Momordicin I – II (Bitter Melon Cucurbitane Triterpene · Anti-inflammatory · STAT3 Inhibitor)

Compound	Momordicin I & II (Momordicoside)
Chemical class	Terpenoid — Triterpene (Cucurbitane-type; highly oxidised tetracyclic triterpene glycosides)
CAS	Momordicin I: 107779-83-9 / Momordicin II: 107779-85-1
Primary source	Momordica charantia (bitter melon / bitter gourd, fruit and seeds)
Key applications	Anti-inflammatory; antiproliferative; antidiabetic; cytotoxic bitter principle; STAT3 inhibitor
Claim strength	Moderate
Typical form	Bitter melon extract (co-delivered with charantin); momordicin isolate (research grade)
Buy from Herbuno	Bitter Gourd Powder - Momordica charantia | Karela → Momordica charantia (Bitter Melon) Extract Powder →

Name origin: From Momordica (the genus; Latin mordere = to bite, referring to the jagged seed margins). Momordicins are cucurbitane-type triterpene glycosides — members of the same tetracyclic triterpene family as cucurbitacins, but less oxidised and less cytotoxic than the highly toxic cucurbitacins. The cucurbitane skeleton is unique to the Cucurbitaceae (gourd family) and is characterised by a methyl group at C-9 (instead of the usual C-10 position of sterols), giving a distinctive structural rearrangement from other triterpene classes. Bitter taste: Momordicins are primary contributors to bitter melon’s intensely bitter taste — the characteristic flavour that defines karela both as a culinary and medicinal plant. The bitterness is a deterrent to over-consumption at food doses, providing a natural safety mechanism. Bitter taste also activates bitter taste receptors (TAS2Rs) in the GI tract, stimulating digestive enzyme secretion and bile flow — contributing to the digestive benefits of bitter melon. Research trajectory: Momordicins have been investigated for anti-inflammatory, antiproliferative, and antidiabetic activity as part of the bitter melon pharmacological profile. Their cucurbitane scaffold gives them inherent STAT3-inhibiting and NF-κB-inhibiting activity similar to related cucurbitacins but with better tolerability. Commercial source: Delivered via Bitter Gourd/Karela extract from Herbuno alongside charantin and vicine.

---

Evidence for Momordicin Applications

Anti-inflammatory — NF-κB and COX inhibition: Momordicins inhibit NF-κB nuclear translocation and COX-2 expression in macrophage models. Animal studies show anti-inflammatory activity in carrageenan-induced paw oedema models. The anti-inflammatory effect of momordicins contributes to bitter melon’s traditional use in inflammatory conditions beyond diabetes. Claim strength: Moderate (in vitro; animal).

Antidiabetic — AMPK activation: Momordicins activate AMPK in hepatocytes and adipocytes, complementing charantin’s GLUT4-translocation mechanism. Momordicin-enriched bitter melon preparations show additive glycaemic benefit with charantin in animal diabetic models. Claim strength: Moderate (animal; indirect human via bitter melon whole extract).

Antiproliferative — STAT3 inhibition: Momordicins inhibit STAT3 signalling in cancer cell models (colorectal, breast) — a mechanism shared with cucurbitacins but at lower, better-tolerated concentrations. The cucurbitane scaffold’s inherent STAT3 interaction translates to antiproliferative activity across multiple cancer cell lines. Claim strength: Emerging (preclinical; no clinical translation).

---

Frequently Asked Questions — Momordicin

How do momordicins differ from cucurbitacins in toxicity?
Both are cucurbitane-type triterpenes but differ dramatically in oxidation state and cytotoxicity. Cucurbitacins (from colocynth, cucumber, Bryonia) are highly oxidised, intensely cytotoxic compounds causing severe GI toxicity and cell death at low concentrations — responsible for the toxicity of bitter plants in the Cucurbitaceae outside of cultivated bitter melon. Momordicins in bitter melon are less oxidised cucurbitane derivatives with significantly lower cytotoxicity, explaining why bitter melon is consumed as a food at normal dietary doses while colocynth (containing cucurbitacins) is a violent purgative. The structure-toxicity relationship in cucurbitanes is steep.

Do momordicins contribute to bitter melon’s bitterness?
Yes — alongside vicine and charantin’s minor bitterness, momordicins are the primary contributors to bitter melon’s characteristic intense bitterness. The bitter taste activates TAS2R bitter taste receptors in the oral cavity and GI tract. GI bitter receptor activation stimulates gastric acid secretion, digestive enzyme release, and bile flow — the “bitters” effect well-established in European phytomedicine for digestive tonics (gentian, artichoke, dandelion). This bitter receptor-mediated digestive stimulation may contribute independently to bitter melon’s glucose-modulating effects by improving carbohydrate digestion pacing.

Can momordicins be used topically?
Bitter melon preparations have traditional use in some cultures for topical applications — wound healing and skin conditions. Momordicins’ anti-inflammatory and antimicrobial properties provide mechanistic support. At concentrations in whole bitter melon juice or extract applied topically, momordicins are unlikely to cause irritation. For cosmeceutical applications, bitter melon extract (containing momordicins + charantin + other actives) could be positioned as an anti-inflammatory skin active, though specific momordicin topical clinical evidence is absent.

What is the momordicin content of standard bitter melon extract?
Momordicin content varies by bitter melon variety, growing region, and fruit maturity. Most commercial bitter melon extracts are not standardised to momordicin content specifically — they are standardised to charantin or total bitter principles. Momordicin I and II are detectable by HPLC-MS at 0.1–2% of dry extract weight in typical preparations. For research applications requiring defined momordicin content, request HPLC-MS analytical certification from Herbuno for lot-specific quantification.

Related compounds: Charantin, Cucurbitacin, Friedelin, Parthenolide

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery